Hoth Therapeutics Granted 180 Day Extension by Nasdaq to Regain Compliance with Bid Price RulePRNewsWire • 06/29/22
Hoth Therapeutics Announces HREC Approval in Australia for the Next Phase of its Trial of BioLexa for Patients with Atopic DermatitisPRNewsWire • 06/21/22
Hoth Announces Adjournment of Annual Meeting of Shareholders Until June 23, 2022PRNewsWire • 06/15/22
Hoth Therapeutics Announces Extension of Washington University Alzheimer's Mouse Model Study with Alzheimer's Therapeutic HT-ALZPRNewsWire • 06/09/22
Hoth Therapeutics Announces Preliminary Efficacy Findings From Phase 1b Clinical Trial with Mild to Moderate Atopic Dermatitis Patient CohortPRNewsWire • 05/03/22
Hoth Therapeutics Announces New Pipeline Asset, HT-TBI for Stroke and Traumatic Brain InjuryPRNewsWire • 04/19/22
Hoth Therapeutics, Inc. Announces Closing of $7.0 Million Underwritten Public Offering Priced At-The-MarketPRNewsWire • 04/14/22
Hoth Therapeutics Announces Acceptance to Present HT-ALZ Proof-of-Concept Alzheimer's Disease Data at the 2022 Alzheimer's Association International ConferencePRNewsWire • 04/12/22
Hoth Therapeutics, Inc. Announces Pricing of $7.0 Million Underwritten Public Offering Priced At-The-MarketPRNewsWire • 04/12/22
Hoth Therapeutics' Novel Cancer Drug Prevented Cell Growth, Induced Cell Death Over 72 hoursBenzinga • 04/11/22
Hoth Therapeutics mRNA Frame-Shifting Therapeutic, HT-KIT, Proves Effective Against Aggressive Cancer CellsPRNewsWire • 04/11/22
Hoth Therapeutics Announces Pipeline Presentation at the 2022 BIO International ConventionPRNewsWire • 04/01/22
Hoth Therapeutics Announces it Has Successfully Completed Manufacturing Feasibility of the HT-KIT Drug SubstancePRNewsWire • 03/22/22
Hoth Therapeutics Announces Orphan Drug Designation Granted to Cancer Therapeutic HT-KIT to Treat MastocytosisPRNewsWire • 03/11/22
Hoth Therapeutics Announces the selection of NUVISAN for Manufacturing HT-001 Drug Batches for CLEER-001 Clinical Study for Cancer PatientsPRNewsWire • 02/09/22
Hoth Therapeutics Announces Presentation of the HT-ALZ Proof-of-Concept Alzheimer's Disease Preclinical Data at the 2022 Alzheimer's Association International ConferencePRNewsWire • 02/07/22
Hoth Therapeutics Announces the Appointment of John Cirrito, PhD and Carla Yuede, PhD to Oversee Alzheimer's Therapeutic Program as Part of Hoth Scientific Advisory BoardPRNewsWire • 01/31/22